We recently published a list of 15 Best Large-Cap Value Stocks to Buy as the Recession Hits. In this article, we are going to ...

The first-quarter earnings season is heating up—both in tempo and the numbers themselves.

Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (SNSE:PFECL) from Buy to Neutral. There are 4,005 funds or institutions reporting positions in Pfizer.

Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (NYSE:PFE) from Buy to Neutral. Analyst Price Forecast Suggests 39.12% Upside As of April 1, 2025 ...

Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (BIT:1PFE) from Buy to Neutral. As of April 4, 2025, the average one-year price target for Pfizer is €28. ...

BMY), Pfizer (NYSE:PFE), and AbbVie (NYSE:ABBV). Eli Lilly (LLY) has ended a three-day selloff after Goldman Sachs analyst Asad Haider upgraded the Indiana-based drugmaker to Buy from Neutral ...

In today’s CEO Daily: Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political ...

Goldman also downgraded Pfizer to Neutral and slashed its price target to $25 from $32, citing ongoing pressures in the base business and a lack of near-term catalysts. The firm said that while ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

On this episode of Stock Movers: - Goldman Sachs (GS) shares are higher after ... maintaining her $225 price target. - Pfizer (PFE) is down today as it plans to abandon its obesity pill ...

Goldman Sachs (GS) shares rise after stock traders ... according to a statement Monday. - Pfizer (PFE) shares edge lower after it halted development of its highest profile experimental drug ...